Bone Demineralization in Postmenopausal Women: Role of Anamnestic Risk Factors

Table 1

Bone mineral density (BMD), TSH and markers of osteoblastic and osteoclastic activities before (T0) and two years (T2) after treatment with L-thyroxin in 110 postmenopausal patients with nodular thyroid disease.

	T0	T1
BMD (T-score)	−0.22±0.07	−1.02±0.10^∗
TSH (μIU/mL)	1.3±0.1	0.8±0.07^∗
Serum calcium concentration (mg/dL)	8.9±0.02	8.8±0.03
Urinary calcium excretion (mg/24 h)	183.2±3.1	190.4±3.3
Alkaline phosphatase (UI/L)	169.7±2.5	188.6±2.3^∗
Urinary hydroxyproline excretion (mg/m^2/24 h)	12.8±0.6	15.7±0.4^∗

^∗𝑃<0.001 versus T0.
Normal values: TSH: 0.49–4.67 μU/L; serum calcium concentration: 8.2–10.5 mg/dL; urinary calcium excretion: 50–250 mg/24 h; alkaline phosphatase: 98–279 UI/L; urinary hydroxyproline excretion (22–65 yrs): 6–22 mg/m²/24 h.